Phase I STTR grant supporting ProFine® study

MetCure received a $160,996 Phase I Small Business Technology Transfer (STTR) grant from the National Cancer Institute. This project is to investigate the efficacy of a novel nutraceutical agent ProFine® in enhancing standard prostate cancer therapy.